Cannabidiol Market (2026 - 2033) Size, Share & Trends Analysis Report By Source (Hemp Derived CBD, Marijuana Derived CBD), By Product (OTC CBD Products), By Application, By Formulation, By Distribution Channel, By Region, And Segment Forecasts

Cannabidiol Market Summary

The global cannabidiol market size was estimated at USD 18.20 billion in 2025 and is projected to reach USD 39.74 billion by 2033, growing at a CAGR of 9.9% from 2026 to 2033. The market is expected to grow with the increasing legalization of hemp-based products. 

Companies are developing a variety of cannabidiol products, including edibles, topical, and beverages, to meet the demand from consumers. The rise of e-commerce has allowed companies to reach a wider audience and increase sales through online channels. The section below outlines the key factors driving the growth of the cannabidiol market, highlighting the rising consumer demand and retail expansion of CBD products, growth in e-commerce and retail access and increasing use of Marijuana across various countries.

Market Drivers

Growing R&D Focus and Market Competition in Cannabidiol

Growing interest in the potential health benefits of cannabidiol has spurred increased investment in research and development to understand its effects better and develop new products. The cannabidiol market is becoming more competitive, with a growing number of companies entering the market and offering similar products. For instance, in October 2025, UK-based Ananda Pharma initiated a Phase I clinical trial for its CBD-based drug candidate (MRX1) targeting conditions such as endometriosis and chemotherapy pain. The company collaborated with academic institutions and sought significant funding to advance development.

Rising Consumer Demand and Retail Expansion of CBD Products

Growing recognition of the therapeutic benefits of cannabidiol has driven consumers to purchase these products, and commercial retailers are focusing on selling cannabis-based items, which have a higher profit margin. For instance, in December 2025, CVS Health highlighted the expansion of its consumer health and wellness product portfolio through its Investor Day announcement, reflecting increased retail focus on high-margin categories such as OTC and plant-based wellness products, including cannabidiol offerings. 

Growth in E-commerce and Retail Access

The expansion of e-commerce platforms and wider retail availability has emerged as a key driver for the global cannabidiol (CBD) market. Online channels enable CBD companies to reach a broader and more diverse consumer base across geographies, overcoming regulatory and distribution barriers associated with physical retail. E-commerce also allows brands to offer detailed product information. For instance, in June 2024, Formula Swiss expanded its digital footprint by launching new online stores in Sweden and Finland, enabling direct-to-consumer access to its certified organic CBD products across additional European markets.

Rising cross-border imports and exports are shaping European CBD supply chains

The European cannabidiol (CBD) and broader cannabis market is increasingly driven by expanding cross-border trade, as ongoing demand to outpace domestic production across key markets. Europe remains highly import-dependent, particularly for medical cannabis and CBD inputs, with Germany serving as the primary demand hub. In Q1-Q3 2024 alone, Germany imported approximately 39.8 tons of medical cannabis, with nearly 48% sourced from Canada, followed by Portugal and Denmark, highlighting a concentrated supplier base.

The broader European trends indicate that imports are rising rapidly due to a structural supply-demand gap, where patient demand and legalization are advancing faster than domestic cultivation infrastructure. This has led to increased international trade flows, improved logistics networks, and stronger regulatory alignment for pharmaceutical-grade cannabis and CBD products.

Increasing Use of Marijuana Globally

Medical marijuana programs in countries such as Canada, Germany, United Kingdom, and parts of the United States have expanded patient access to cannabis-based therapies for conditions such as chronic pain, epilepsy, anxiety, and multiple sclerosis. As CBD is a non-psychoactive compound derived from cannabis, its demand has grown alongside the broader acceptance of marijuana use.

In addition, increasing consumer awareness of the therapeutic benefits of cannabis has led to higher adoption rates in both developed and emerging markets. Countries in Latin America and Asia-Pacific are also gradually relaxing regulations, further contributing to market expansion. The normalization of cannabis consumption has supported by healthcare professionals, research institutions, and evolving legal frameworks has encouraged the development and commercialization of CBD-infused products across pharmaceuticals, wellness, food & beverages, and personal care sectors.

Market Concentration & Characteristics

The chart below represents the relationship between industry concentration, industry characteristics, and industry participants. There is a medium to high degree of innovation, a moderate level of merger & acquisition activities, and moderate geographic expansion.

The degree of innovation is moderately high, driven by continuous advancements in formulations, delivery systems, and application areas. Companies are actively investing in R&D to develop next-generation cannabinoid products such as water-soluble CBD, nano-emulsified formulations, and condition-specific therapeutics, improving bioavailability and efficacy. For instance, in April 2026, bdMD, Inc, a science-driven cannabinoid products company, announced the launch of its clinical healthcare channel, positioning the Company to support physicians, health systems, and value-based care organizations as federal policy establishes structured pathways for hemp-derived cannabinoid products within Medicare programs.

The level of mergers and acquisitions (M&A) in the global cannabidiol (CBD) market is increasing significantly as companies seek to strengthen their market position, expand product portfolios, and achieve geographic diversification. In March 2025, Xebra Brands Ltd. Partnered with of BSK Holdings Inc. to strengthen its presence in the North American CBD market.

The legalization of medical cannabis and evolving frameworks for CBD usage across countries have significantly boosted market growth. While favorable regulatory reforms such as cannabis rescheduling and legalization open new revenue streams and attract investments, stringent compliance requirements can increase operational costs and delay product launches.

The CBD companies are expanding into emerging markets and capitalize on evolving legalization trends globally. Firms are expanding into regions such as Europe, Latin America, and Asia-Pacific, where regulatory frameworks are gradually becoming more supportive of cannabis-derived products. For instance,in October 2025, Releaf expanded its operations into Germany to strengthen its presence in the European medical cannabis market. This move aimed to improve patient access and cross-border distribution of cannabis-based therapies, reflecting the growing trend of regional expansion among European cannabidiol (CBD) and medical cannabis companies.

Source Insights

The hemp-derived CBD segment dominated the market and generated 52.9% of the revenue in 2025, due to rising demand from the pharmaceutical industry and growing consumer awareness of health benefits. Legalizing medicinal cannabis and growing consumer disposable income are also expected to boost the demand for cannabidiol in the pharmaceutical sector. For instance, in February 2026, Jazz Pharmaceuticals plc expanded its hemp-derived CBD portfolio by strengthening the global distribution of its CBD-based epilepsy treatment, Epidiolex. 

The Marijuana-derived CBD segment is expected to grow significantly over the forecast period. It has a higher cannabinoid concentration and is increasingly used in specialized therapeutic applications in oncology, chronic pain, and neurological disorders. Unlike hemp-derived CBD, marijuana-derived formulations contain higher THC levels enhancing therapeutic efficacy in certain treatments under medical supervision. For instance, in February 2026, Aurora Cannabis Inc. announced the expansion of its medical cannabis portfolio in Europe, particularly in Germany and the UK, by supplying high-THC and balanced CBD cannabis formulations for patients through pharmacies and healthcare providers.

Product Insights

The OTC CBD products segment held the largest revenue share of 71.9% in 2025, driven by factors such as growing consumer awareness regarding CBD’s perceived health benefits and the increasing preference for natural and plant-based alternatives. Additionally, regulatory relaxations for hemp-derived CBD in several countries have enabled companies to commercialize OTC CBD products at scale. The expansion of product formats such as gummies, cosmetics, and functional beverages has further enhanced consumer adoption. For instance, in October 2025, Charlotte’s Web Holdings, Inc. announced the expansion of its OTC CBD wellness product portfolio, including gummies and functional supplements, to strengthen its presence across retail and e-commerce channels. The company emphasized rising consumer demand for non-prescription CBD products for daily wellness.

The Pharmaceutical-grade CBD (Rx formulations) segment is anticipated to grow at the fastest CAGR over the forecast period, due to increasing clinical validation, regulatory approvals, and physician adoption of cannabinoid-based therapies. Unlike OTC products, prescription (Rx) CBD formulations undergo rigorous clinical trials and regulatory scrutiny, ensuring standardized dosing, safety, and efficacy. The segment is gaining traction particularly in the treatment of epilepsy, neurological disorders, and rare diseases, where high-purity CBD formulations are required. The growing pipeline of cannabinoid-based drugs and rising investments in clinical research are further accelerating segment growth. For instance, in December 2025, Jazz Pharmaceuticals plc announced new clinical and real-world data for its prescription CBD drug Epidiolex at the American Epilepsy Society Annual Meeting, reinforcing its effectiveness in treating rare forms of epilepsy and supporting continued expansion of pharmaceutical-grade CBD adoption globally.

Application Insight

The medical/therapeutic use segment held the largest revenue share of 38.9% in 2025. The growth can be attributed to the increasing clinical validation of CBD for treating chronic conditions such as epilepsy, anxiety, multiple sclerosis, and chronic pain. Growing physician acceptance and rising patient awareness regarding cannabinoid-based therapies have further strengthened demand in this segment. For instance, in March 2025, Cantourage Group SE reported strong growth in its medical cannabis business across Europe, driven by increasing patient access and demand for cannabinoid-based therapies.

The food & beverage segment is anticipated to grow at the fastest CAGR over the forecast period, driven by the rising consumer shift toward functional and wellness-oriented products. Consumers are increasingly seeking natural ingredients that support stress relief, relaxation, and overall well-being, positioning CBD as a key additive in beverages such as infused water, teas, and functional drinks. For instance in July 2025, SNDL Inc. expanded its Cannabis 2.0 portfolio, including CBD-infused beverages and ingestible, focusing on functional wellness products and highlighting the growing commercialization of CBD in everyday consumables.

Formulation Insights

The full-spectrum CBD segment held the 40.4% share in 2025, driven by growing product availability across oils, tinctures, capsules, and topicals, along with increasing acceptance of trace THC content in regulated markets. For instance, in March 2025, Nordic Oil strengthened its product portfolio by expanding its range of full-spectrum CBD oils and wellness products, focusing on high-quality, terpene-rich formulations to enhance the entourage effect.

The broad-spectrum CBD segment is anticipated to grow at the fastest CAGR from 2026 to 2033, driven by rising demand for THC-free or zero-THC formulations. The segment is gaining traction particularly among health-conscious consumers, working professionals, and athletes, where THC consumption may be restricted due to drug testing concerns. In addition, increasing regulatory scrutiny in several countries has encouraged manufacturers to develop compliant, THC-free formulations, further boosting adoption.

Distribution Channel Insights

The e-commerce / online platforms segment held the 30.7% share in 2025, driven by growing preference for convenience, wider product availability, and discreet purchasing options. Consumers increasingly prefer online channels for CBD products due to access to detailed product information, reviews, and competitive pricing. In addition, the expansion of direct-to-consumer (DTC) strategies by CBD companies and the increasing penetration of digital payment systems have significantly boosted online sales. Subscription-based models and personalized wellness recommendations are further enhancing customer retention in this segment. For instance, in June 2024, Formula Swiss expanded its digital footprint by launching new online stores in Sweden and Finland, enabling direct-to-consumer access to its certified organic CBD products across additional European markets.

The supermarkets/hypermarkets segment is anticipated to grow at the fastest CAGR over the forecast period, driven by the increasing mainstream acceptance of CBD products and their integration into organized retail chains. As regulatory clarity improves in several regions, large retail chains are increasingly incorporating CBD products into their health, wellness, and functional food sections, making them more accessible to mass consumers. For instance, in May 2024, Goodrays expanded its CBD-infused drinks distribution across major UK retail chains, making its products available in supermarkets and large-format stores.

Regional Insights

North America cannabidiol (CBD) market dominated the global market with a revenue share of 66.5%. North America is expected to experience significant growth in the cannabidiol market due to several factors, such as a large number of health-conscious individuals, growing acceptance of CBD products, the presence of major manufacturers, and the approval of the U.S. Farm Bill in 2020. The region is considered the most advanced in cannabis and its products, including cannabidiol, with the highest number of CBD companies and favorable laws regarding the use of CBD products.

U.S. Cannabidiol (CBD) Market Trends

The U.S. dominated the cannabidiol (CBD) market in the North America region in 2025, driven by its highly developed cannabis ecosystem, favorable regulatory framework, and strong consumer demand for CBD-based wellness and medical products, and increasing expansion by companies in the region. North America accounted for a significant share of the global CBD market, with the U.S. contributing the majority of regional revenue due to widespread legalization of hemp-derived CBD under federal law and supportive state-level regulations. For instance, in April 2025, The Cannabist Company announced adult-use sales at Cannabist Mays Landing being the Company’s third dispensary in the Garden State. 

Europe Cannabidiol (CBD) Market Trends

Cannabidiol (CBD) market in Europe is expected to grow significantly over the forecast period. Increasing awareness concerning the health benefits among consumers, easy availability, and affordable prices have resulted in the increased popularity of CBD oil in this region. Increasing awareness concerning the health benefits among consumers, easy availability, and affordable prices have resulted in the increased popularity of CBD oil in the UK.  For instance, in March 2025, Bedrocan introduced a high-CBD cannabis raw material (Bedrolina) at Vitafoods Europe, designed for use in nutraceutical and wellness formulations. The product contains high CBD content with less than 1% THC, making it suitable for developing broad-spectrum and low-THC CBD products aligned with European regulatory standards.

Cannabidiol (CBD) market in Germany held the largest revenue in 2025, driven by established regulatory framework, early legalization of medical cannabis, and a strong healthcare infrastructure. The country allows prescription-based access to cannabis through a wide pharmacy network, significantly boosting medical CBD adoption. Increasing acceptance of cannabis for both therapeutic and wellness applications, along with supportive reimbursement systems, has strengthened market penetration. Germany’s regulatory clarity and high consumer awareness continue to attract investments and product innovation, positioning it as the leading market in Europe.

Poland cannabidiol Market is expected to grow significantly from 2026 to 2033, driven by rising patient demand for medical cannabis, increasing awareness of CBD’s therapeutic benefits, and gradual regulatory development. Although the market has experienced regulatory adjustments (such as restrictions on telemedicine prescriptions), it has demonstrated resilience with recovery in product demand and distribution through structured healthcare channels. Expanding access through pharmacies and improving regulatory clarity are expected to further support Poland’s long-term market expansion, making it a key growth hub in the European CBD landscape.

Asia Pacific Cannabidiol (CBD) Market Trends

Cannabidiol (CBD) market in Asia Pacific is expected to grow significantly over the forecast period, due to the establishment of hemp production facilities, particularly in China. China is the leading hemp grower in Asia, producing nearly half of the world's hemp. It exports most of its CBD based products to the U.S., Germany, the UK, the Netherlands, and Japan and has started growing hemp in three provinces for CBD extraction purposes. The new government policies supporting the industry, low CBD production costs, and unique large-scale manufacturing infrastructure and expertise are anticipated to create intense competition for hemp companies in the U.S., Canada, and the European Union with low-cost CBD supplies.

Cannabidiol (CBD) market in China held the largest revenue in 2025 and is the fastest growing market over the forecast period driven by the country’s strong industrial hemp cultivation capabilities, particularly in provinces such as Yunnan, which are licensed for large-scale CBD extraction and export. China plays a critical role as a global supplier of CBD isolate and raw materials due to its low production costs and advanced processing infrastructure.

Japan cannabidiol (CBD) market is expected to grow significantly over the forecast period due to increasing acceptance of CBD for wellness and therapeutic applications. Japan permits the use of CBD products derived from hemp stalks and seeds, creating a legal pathway for CBD-based imports and product development. The rising consumer interest in natural health supplements, along with an aging population seeking alternative treatments for conditions such as anxiety, sleep disorders, and chronic pain, is driving demand. Furthermore, the expansion of e-commerce platforms and specialty wellness stores has improved product accessibility across the country.

Oceania Cannabidiol (CBD) Market Trends

Oceania region is experiencing significant growth driven by progressive regulatory frameworks and increasing acceptance of cannabis-based therapeutics. Countries in the region, particularly Australia and New Zealand, have implemented structured medical cannabis programs, enabling controlled access to CBD products.

Cannabidiol (CBD) market in Australia is expected to grow significantly due to a well-established regulatory framework and increasing patient access to medical cannabis. The Therapeutic Goods Administration (TGA) has enabled access to CBD products through prescription pathways, such as the Special Access Scheme (SAS) and Authorised Prescriber Scheme, facilitating broader adoption. Growth is further driven by rising awareness of CBD’s benefits in managing conditions such as chronic pain, anxiety, and sleep disorders

Latin America & Caribbean Cannabidiol (CBD) Market Trends

Latin America and Carribbean CBD market is expected to grow significantly over the forecast period, driven by favorable climatic conditions for cannabis cultivation, evolving regulatory frameworks, and increasing foreign investments. Countries such as Brazil, and Colombia are gradually legalizing and regulating cannabis for medical and industrial use, creating growth opportunities.

Cannabidiol (CBD) market in Brazil is expected to grow significantly over the forecast period, driven by evolving regulatory support, increasing medical adoption, and rising demand for alternative therapies. The market is witnessing strong expansion as Brazil continues to refine its legal framework for cannabis-based products under the supervision of the National Health Surveillance Agency (ANVISA).

Africa Cannabidiol (CBD) Market Trends

The Africa Cannabidiol (CBD) Market is witnessing gradual but steady growth, driven by increasing awareness regarding the therapeutic benefits of cannabidiol in managing chronic pain, anxiety, epilepsy, and sleep disorders, along with the rising cultivation of industrial hemp in select African countries. Governments in countries such as South Africa and Lesotho are increasingly supporting cannabis-related reforms and medical cannabis cultivation, creating opportunities for CBD-based pharmaceuticals, wellness products, cosmetics, and nutraceuticals. For instance, South Africa legalized the private use of cannabis and has established a regulatory framework for medical cannabis production, encouraging companies to launch CBD oils, capsules, and skincare products through pharmacies and wellness channels.

Recent Developments

• In October 2025, Releaf expanded its operations into Germany to strengthen its presence in the European medical cannabis market. This move aimed to improve patient access and cross-border distribution of cannabis-based therapies, reflecting the growing trend of regional expansion among European CBD and medical cannabis companies.

• In October 2025, CR Wellness partnered with the global cannabis brand Cookies to launch premium cannabis and CBD wellness products in Brazil, marking Cookies’ entry into South America’s largest market. The rollout begins with prescription-only THC/CBD tinctures and gummies, supported by full regulatory compliance and lab testing.

• In October 2025, medical cannabis wellness startup Awshad launched a 6500 mg CBD oil aimed at managing chronic pain and severe conditions, marking its most potent formulation to date. The launch coincided with the company achieving profitability in its fourth year, reflecting rising acceptance of cannabis-based wellness in India.

• In September 2025, the UK Food Standards Agency opened a consultation on approving the first CBD food products as novel foods in Great Britain. The review covers three applications and proposes mandatory safety warnings, signalling progress toward formal regulation of CBD foods in the UK.

• In March 2025, Bedrocan introduced a high-CBD cannabis raw material (Bedrolina) at Vitafoods Europe, designed for use in nutraceutical and wellness formulations. The product contains high CBD content with less than 1% THC, making it suitable for developing broad-spectrum and low-THC CBD products aligned with European regulatory standards.

• In June 2024, Rodedawg International Industries, Inc., a cannabis manufacturer and distributor, introduced the Nutrient CBD, which includes five innovative SKUs, such as two CBD Oil Tinctures, two CBD Creams, and one CBD Roll-On, to meet the various needs of consumers seeking natural and effective wellness solutions.

Cannabidiol Market Report Scope

Global Cannabidiol Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global cannabidiol market based on source, product, application, formulation, distribution channel, and region:

• Source Outlook (Revenue, USD Million, 2021 - 2033)

  • Hemp-derived CBD

  • Marijuana derived CBD

• Product Outlook (Revenue, USD Million, 2021 - 2033)

  • OTC CBD Products

    • CBD Oil & Tinctures (Drops)

    • CBD Capsules

    • Topicals (Creams, Balms, Skincare)

    • Edibles (Gummies, Beverages, Functional Foods)

    • Vape Products

  • Pharmaceutical-grade CBD (Rx formulations)

    • Oral solutions (CBD Oils, Tinctures/Drops)

    • Capsules

• Application Outlook (Revenue, USD Million, 2021 - 2033)

  • Medical / Therapeutic Use

  • Wellness & Lifestyle

  • Personal Care & Cosmetics

  • Food & Beverage

  • Others (Pet care, niche uses)

• Formulation Outlook (Revenue, USD Million, 2021 - 2033)

  • Full-spectrum CBD

  • Broad-spectrum CBD

  • CBD Isolate

• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)

  • E-commerce / Online Platforms

  • Retail Pharmacies

  • Specialty Stores (CBD stores, wellness shops)

  • Supermarkets/Hypermarkets

  • Hospitals & Clinics (Rx CBD)

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • Italy

    • France

    • Netherlands

    • Switzerland

    • Spain

    • Poland

    • Czech Republic

    • Croatia

  • Asia

    • China

    • India

    • Japan

    • Thailand

  • Oceania

    • Australia

    • New Zealand

  • Latin America & Caribbean

    • Brazil

    • Uruguay

    • Colombia

    • Argentina

  • Africa